Efficacy of fecal microbiota therapy in steroid dependent ulcerative colitis: a real world intention-to-treat analysis = Efficacy of fecal microbiota therapy in steroid dependent ulcerative colitis: a real world intention-to-treat analysis

다국어 초록 (Multilingual Abstract)

Background/Aims: Four high-quality randomized controlled trials have proven the efficacy of fecal microbiota transplantation (FMT) in active ulcerative colitis (UC). We assessed the efficacy of FMT in a real-world setting involving steroid-dependent patients with UC. Methods: This was a single-center prospective analysis of data from steroid-dependent patients with UC treated with FMT from September 2015 to September 2017 at the Dayanand Medical College, a tertiary care center in India. Fecal samples from random unrelated donors were administered through colonoscopy at weeks 0, 2, 6, 10, 14, 18, and 22. The primary outcome was achievement of steroid-free clinical remission, and the secondary outcomes were clinical response and endoscopic remission at 24 weeks. Modified intention-to-treat analysis was performed, which included subjects who underwent at least 1 FMT. Results: Of 345 patients with UC treated during the study period, 49 (14.2%) had steroid-dependent UC. Of these 49 patients, 41 underwent FMT: 33 completed 7 sessions over 22 weeks according to the protocol, and 8 discontinued treatment (non-response, 5; lost to follow-up, 2; and fear of adverse effects, 1). At week 24, steroid-free clinical remission was achieved in 19 out of 41 (46.3%) patients, whereas clinical response and endoscopic remission were achieved in 31 out of 41 (75.6%) and 26 out of 41 (63.4%) patients, respectively. All patients with clinical response were able to withdraw steroids. There were no serious adverse events necessitating discontinuation. Conclusions: A multisession FMT via the colonoscopic route is a promising therapeutic option for patients with steroid-dependent UC, as it can induce clinical remission and aid in steroid withdrawal. (Intest Res 2019;17:78-86)

참고문헌 (Reference)

1 Natalie Grace Fairhurst, "Why is it so difficult to evaluate faecal microbiota transplantation as a treatment for ulcerative colitis?" 대한장연구학회 16 (16): 209-215, 2018

2 Lewis JD, "Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis" 14 : 1660-1666, 2008

3 Adler DJ, "The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis" 85 : 717-722, 1990

4 Damman CJ, "The microbiome and inflammatory bowel disease : is there a therapeutic role for fecal microbiota transplantation" 107 : 1452-1459, 2012

5 Agrawal M, "The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146elderly individuals" 50 : 403-407, 2016

6 Fraser AG, "The efficacy of azathioprine for the treatment of inflammatory bowel disease : a 30 year review" 50 : 485-489, 2002

7 Satsangi J, "The Montreal classification of inflammatory bowel disease : controversies, consensus, and implications" 55 : 749-753, 2006

8 Angelberger S, "Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation" 108 : 1620-1630, 2013

9 Narula N, "Systematic review and meta-analysis : fecal microbiota transplantation for treatment of active ulcerative colitis" 23 : 1702-1709, 2017

10 Ekbom A, "Survival and causes of death in patients with inflammatory bowel disease : a population-based study" 103 : 954-960, 1992

11 Cui B, "Step-up fecal microbiota transplantation strategy : a pilot study for steroid-dependent ulcerative colitis" 13 : 298-, 2015

12 Costello SP, "Short duration, low intensity, pooled fecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis : a randomised controlled trial" 152 : S198-, 2017

13 Kunde S, "Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis" 56 : 597-601, 2013

14 Britton RA, "Role of the intestinal microbiota in resistance to colonization by Clostridium difficile" 146 : 1547-1553, 2014

15 Manichanh C, "Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach" 55 : 205-211, 2006

16 Ardizzone S, "Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis" 55 : 47-53, 2006

17 Paramsothy S, "Multidonor intensive faecal microbiota transplantation for active ulcerative colitis : a randomised placebo-controlled trial" 389 : 1218-1228, 2017

18 Serban DE, "Microbiota in inflammatory bowel disease pathogenesis and therapy : is it all about diet" 30 : 760-779, 2015

19 Peterson DA, "Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases" 3 : 417-427, 2008

20 Damman CJ, "Low level engraftment and improvement following a single colonoscopic administration of fecal microbiota to patients with ulcer ative colitis" 10 : e0133925-, 2015

21 Armuzzi A, "Infliximab in steroiddependent ulcerative colitis : effectiveness and predictors of clinical and endoscopic remission" 19 : 1065-1072, 2013

22 Rutgeerts P, "Infliximab for induction and maintenance therapy for ulcerative colitis" 353 : 2462-2476, 2005

23 Walker AW, "High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and noninflamed regions of the intestine in inflammatory bowel disease" 11 : 7-, 2011

24 Rossen NG, "Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis" 149 : 110-118, 2015

25 Uygun A, "Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis" 96 : e6479-, 2017

26 Moayyedi P, "Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial" 149 : 102-109, 2015

27 Girotra M, "Fecal microbiota transplantation for recurrent Clostridium difficile infection in the elderly : long-term outcomes and microbiota changes" 61 : 3007-3015, 2016

28 Colman RJ, "Fecal microbiota transplantation as therapy for inflammatory bowel disease : a systematic review and meta-analysis" 8 : 1569-1581, 2014

29 Suskind DL, "Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis" 60 : 27-29, 2015

30 Vermeire S, "Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease" 10 : 387-394, 2016

31 Gophna U, "Differences between tissue-associated intestinal microfloras of patients with Crohn’s disease and ulcerative colitis" 44 : 4136-4141, 2006

32 Panaccione R, "Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis" 146 : 392-400, 2014

33 Xu L, "Clinical efficacy maintains patients’positive attitudes toward fecal microbiota transplantation" 95 : e4055-, 2016

34 Ren R, "A pilot study of treating ulcerative colitis with fecal microbiota transplantation" 54 : 411-415, 2015